Cargando…

The association between body mass index, demographic and clinical characteristics with cognitive performance in patients with neuromyelitis optica spectrum disorder

Background: Cognitive dysfunction is one of the problems that patients with neuromyelitis optica spectrum disorder (NMOSD) suffer from. We aimed to assess the association between demographic and clinical features as well as body mass index (BMI) and cognitive function in patients with NMOSD. Methods...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rezaeimanesh, Nasim, Saeedi, Roghayyeh, Sahraian, Mohammad Ali, Ghadiri, Fereshteh, Naser Moghadasi, Abdorreza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860205/ https://www.ncbi.nlm.nih.gov/pubmed/38011484 http://dx.doi.org/10.18502/cjn.v21i2.10490

Ejemplares similares

Whole grains and legumes consumption in association with neuromyelitis optica spectrum disorder odds
por: Rezaeimanesh, Nasim, et al.
Publicado: (2021)

Evaluation of COVID-19 infection in patients with Neuromyelitis optica spectrum disorder (NMOSD): A report from Iran
por: Sahraian, Mohammad Ali, et al.
Publicado: (2020)

The possible role of Interleukin-6 as a regulator of insulin sensitivity in patients with neuromyelitis optica spectrum disorder
por: Maghbooli, Zhila, et al.
Publicado: (2021)

Increased Intracranial Pressure on a Patient with Neuromyelitis Optica Spectrum Disorder
por: Forouzannia, Seyed Mohammad, et al.
Publicado: (2021)

The Possible Direct Correlation between Cognitive Impairment and Fear of Catching COVID-19 among Patients with Multiple Sclerosis
por: Saeedi, Roghayyeh, et al.
Publicado: (2021)

Adding erythropoietin to intravenous methylprednisolone in acute treatment of attacks of neuromyelitis optica spectrum disorders: A randomized controlled trial
por: Shafaei, Maryam, et al.
Publicado: (2022)

Association of body mass index and physical activity with fatigue, depression, and anxiety among Iranian patients with multiple sclerosis
por: Rezaeimanesh, Nasim, et al.
Publicado: (2023)

Attitudes toward vaccination in patients with multiple sclerosis: A report from Iran
por: Ghadiri, Fereshteh, et al.
Publicado: (2021)

Eculizumab in the treatment of neuromyelitis optica spectrum disorder
por: Nabizadeh, Fardin, et al.
Publicado: (2023)

Is Body Mass Index (BMI) Associated with Risk and Outcomes of COVID-19 in Iranian Multiple Sclerosis Patients?
por: Rezaeimanesh, Nasim, et al.
Publicado: (2023)

Disability and Therapeutic Response in Paediatric Neuromyelitis Optica Spectrum Disorder: A Case Series from Iran
por: BAGHBANIAN, Seyed Mohammad, et al.
Publicado: (2019)

Association of cigarette smoking with neuromyelitis optica-immunoglobulin G sero-positivity in neuromyelitis optica spectrum disorder
por: Eskandarieh, Sharareh, et al.
Publicado: (2019)

Prevalence of COVID-19 infection in patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2021)

Efficacy and safety of rituximab in patients with refractory neuromyelitis optica spectrum disorders: A prospective observation in Iranian cases
por: Seyed Ahadi, Maral, et al.
Publicado: (2020)

The effect of body mass index on the morbidity and outcomes of COVID-19 in Iranian patients with multiple sclerosis
por: Rezaeimanesh, Nasim, et al.
Publicado: (2023)

Evaluation of the Opinion of Patients With Multiple Sclerosis on the Outcomes of Catching COVID-19 and Its Effects on the MS Symptoms
por: Rezaeimanesh, Nasim, et al.
Publicado: (2020)

Neuromyelitis optica with linear enhancement of corpus callosum in brain magnetic resonance imaging with contrast: a case report
por: Sahraian, Mohammad Ali, et al.
Publicado: (2015)

Telemedicine as a strategic intervention for cognitive rehabilitation in MS patients during COVID-19
por: Ghadiri, Fereshteh, et al.
Publicado: (2022)

Association of cognitive impairment and quality of life in patients with multiple sclerosis: A cross-sectional study
por: Nabizadeh, Fardin, et al.
Publicado: (2022)

Assessment of COVID-19 vaccine attitude in people with multiple sclerosis, its correlation with demographic factors, and fear of coronavirus: A cross-sectional survey
por: Fattahi, Mohammad Reza, et al.
Publicado: (2022)

Beta-thalassemia intermedia with ischemic transients misdiagnosed as multiple sclerosis: A case report
por: Ghadiri, Fereshteh, et al.
Publicado: (2021)

The first presentation of COVID-19 two hours after vaccination in a patient with multiple sclerosis: Can COVID vaccine provoke cytokine storm in a patient with asymptomatic COVID-19?
por: Ghadiri, Fereshteh, et al.
Publicado: (2021)

Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study
por: Seyed Ahadi, Maral, et al.
Publicado: (2021)

Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: What neurologists need to know?
por: Paybast, Sepideh, et al.
Publicado: (2022)

Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV
por: Ali Sahraian, Mohammad, et al.
Publicado: (2021)

The study of COVID-19 infection following vaccination in patients with multiple sclerosis
por: Ghadiri, Fereshteh, et al.
Publicado: (2022)

The perspective of Iranian patients with multiple sclerosis on the third dose of COVID-19 vaccine
por: Ghadiri, Fereshteh, et al.
Publicado: (2022)

Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): A report from Iran
por: Sahraian, Mohammad Ali, et al.
Publicado: (2020)

Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review
por: Ghadiri, Fereshteh, et al.
Publicado: (2023)

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014)

Evaluating the relationship between emotional intelligence and cognitive disorders in patients with Multiple Sclerosis
por: Owji, Mahsa, et al.
Publicado: (2018)

Neuromyelitis Optica Spectrum Disorder
por: Cazzaniga, Juliana, et al.
Publicado: (2023)

Comment on “Alemtuzumab improves cognitive processing speed in active multiple sclerosis – a longitudinal observational study”
por: Asadollahzade, Elnaz, et al.
Publicado: (2022)

Epidemiology of multiple sclerosis in Qom: Demographic study in Iran
por: Rezaali, Saeed, et al.
Publicado: (2013)

Neuromyelitis optica spectrum disorders: An update
por: Pandit, Lekha
Publicado: (2015)

Treatment of Neuromyelitis Optica Spectrum Disorders
por: Chan, Koon-Ho, et al.
Publicado: (2021)

Satralizumab for neuromyelitis optica spectrum disorder
Publicado: (2021)

Spectrum of sublytic astrocytopathy in neuromyelitis optica
por: Guo, Yong, et al.
Publicado: (2021)

Circulating Memory T Follicular Helper Cells in Patients with Neuromyelitis Optica/Neuromyelitis Optica Spectrum Disorders
por: Fan, Xueli, et al.
Publicado: (2016)

Comment on “The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging”
por: Asadollahzade, Elnaz, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s86tll6cup8qrnf7por62vvedp